Published in Br J Cancer on April 01, 1982
The role of gamma-interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology (1987) 2.91
Signal transduction in host cells by a glycosylphosphatidylinositol toxin of malaria parasites. J Exp Med (1993) 2.88
Malarial parasites induce TNF production by macrophages. Immunology (1988) 2.42
Effect of human monocyte killing of tumour cells of antibody raised against an extracellular monocyte cytotoxin. Immunology (1983) 1.07
Oxygen radical production by peritoneal macrophages and Kupffer cells elicited with Lactobacillus casei. Infect Immun (1984) 1.00
Anti-tumour cytotoxin produced by human monocytes: studies on its mode of action. Br J Cancer (1983) 0.99
Sendai virus induces high levels of tumor necrosis factor mRNA in human peripheral blood leukocytes. Nucleic Acids Res (1986) 0.95
Autocrine tumor necrosis factor (TNF) and lymphotoxin (LT) alpha differentially modulate cellular sensitivity to TNF/LT-alpha cytotoxicity in L929 cells. J Cell Biol (1998) 0.80
Anti-tumour cytotoxin from macrophages: no correlation between cytotoxin adsorption by tumour cell lines and their cytotoxin susceptibility. Immunology (1984) 0.78
Involvement of tumour necrosis factor in monocyte-mediated rapid killing of actinomycin D-pretreated WEHI 164 sarcoma cells. Immunology (1986) 0.77
Identity of human B-cell line cytotoxic lymphokine with tumor necrosis factor type beta. Proc Natl Acad Sci U S A (1989) 0.77
Activated macrophages kill tumour cells by releasing arginase. Nature (1978) 3.63
Macrophages as a source of tumoricidal activity (tumor-necrotizing factor). Infect Immun (1980) 3.41
Selective cytotoxicity of peritoneal leucocytes for neoplastic cells. Cell Immunol (1973) 3.17
Tumour-necrosis factor from the rabbit. II. Production by monocytes. Br J Cancer (1978) 2.48
Production of an anti-tumour cytotoxin by human monocytes. Immunology (1981) 1.78
Effector mechanisms of cytolytically activated macrophages. I. Secretion of neutral proteases and effect of protease inhibitors. J Immunol (1980) 1.77
Discrimination between neoplastic and non-neoplastic cells in vitro by activated macrophages. J Natl Cancer Inst (1974) 1.64
Production of the complement cleavage product, C3a, by activated macrophages and its tumorolytic effects. Clin Exp Immunol (1978) 1.46
Tumour-necrosis factor from the rabbit. V. Synthesis in vitro by mononuclear phagocytes from various tissues of normal and BCG-injected rabbits. Br J Cancer (1981) 1.13
Inability of the C3a anaphylatoxin to promote cellular lysis. Nature (1980) 1.07
Selective neutralization by antiinterferon globulin of macrophage activation by L-cell interferon, Brucella abortus ether extract, Salmonella typhimurium lipopolysaccharide, and polyanions. Cell Immunol (1979) 0.97
Interaction of macrophages with tumor cells. Adv Exp Med Biol (1976) 0.92
Tumour-necrosis factor from the rabbit. I. Mode of action, specificity and physicochemical properties. Br J Cancer (1978) 3.38
Tumour-necrosis factor from the rabbit. II. Production by monocytes. Br J Cancer (1978) 2.48
Malarial parasites and tumour cells are killed by the same component of tumour necrosis serum. Clin Exp Immunol (1984) 2.34
Production of an anti-tumour cytotoxin by human monocytes. Immunology (1981) 1.78
Characterization of cytotoxic spleen cells and effects of serum factors in a syngeneic rat tumour system. Br J Cancer (1976) 1.53
Tumour-necrosis factor from the rabbit. IV. Purification and chemical characterization. Br J Cancer (1980) 1.47
Triiodothyronine in the recovery of stunned myocardium in dogs. Ann Thorac Surg (1991) 1.40
Serotonin transporter (5-HTT) and gamma-aminobutyric acid receptor subunit beta3 (GABRB3) gene polymorphisms are not associated with autism in the IMGSA families. The International Molecular Genetic Study of Autism Consortium. Am J Med Genet (1999) 1.31
Tumour-necrosis factor from the rabbit. III. Relationship to interferons. Br J Cancer (1979) 1.23
Studies of lymphocyte transendothelial migration: analysis of migrated cell phenotypes with regard to CD31 (PECAM-1), CD45RA and CD45RO. Immunology (1993) 1.22
Agglutinins to bacteria in Crohn's disease. Gut (1980) 1.19
Involvement of phospholipase A2 activation in tumour cell killing by tumour necrosis factor. Immunology (1988) 1.17
Neutral amino acid uptake by the microvillous plasma membrane of the human placenta is inversely related to fetal size at birth in normal pregnancy. J Clin Endocrinol Metab (1998) 1.15
Tumour-necrosis factor from the rabbit. V. Synthesis in vitro by mononuclear phagocytes from various tissues of normal and BCG-injected rabbits. Br J Cancer (1981) 1.13
Inherited thrombocytopenia, elevated serum IgA and renal disease: identification as a variant of the Wiskott-Aldrich syndrome. Q J Med (1986) 1.12
Effect of human monocyte killing of tumour cells of antibody raised against an extracellular monocyte cytotoxin. Immunology (1983) 1.07
Analysis of inhibition of lymphocyte cytotoxicity in human colon carcinoma. Br J Cancer (1975) 1.07
Immunogenicity of lipid-conjugated antigens. II. Anti-complementary activity and antigen trapping in the spleen. Immunology (1980) 1.04
pABC11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. J Biol Chem (1999) 1.01
Anti-tumour cytotoxin produced by human monocytes: studies on its mode of action. Br J Cancer (1983) 0.99
Coeliac disease associated with auto-immune thyroiditis, Sjogren's syndrome, and a lymphocytotoxic serum factor. Aust N Z J Med (1972) 0.97
A case of hereditary combined deficiency of complement components C6 and C7 in man. Clin Exp Immunol (1989) 0.97
A study of cell mediated and humoral immunity in haemophilia and related disorders. Br J Haematol (1985) 0.97
Human growth hormone in cultures of human pituitary tumors. J Neurosurg (1971) 0.97
Smoking, humoral immunity, and ulcerative colitis. Gut (1991) 0.95
Tumour necrosis factor activity in joint fluids from rheumatoid arthritis patients. Br J Rheumatol (1989) 0.95
Zymosan-induced leukotriene B4 generation by human neutrophils is augmented by rhTNF-alpha but not chemotactic peptide. Immunology (1990) 0.94
Lymphoid cell fractionation by aggregated immunoglobulin-agarose columns. J Immunol Methods (1976) 0.94
Tumour cells which develop resistance to cytolysis by tumour necrosis factor have a different glycoform of a 105-kDa glycoprotein and lose the capacity to invade and metastasize. Int J Cancer (1990) 0.94
Recurrent meningococcal infections associated with a functional deficiency of the C8 component of human complement. Clin Exp Immunol (1980) 0.94
"Spontaneous" cytolysis by normal human lymphocytes of Burkitt's lymphoma cells of the EB2 cell line. Aust J Exp Biol Med Sci (1974) 0.90
Fetuin: an acute phase protein in cattle. J Comp Physiol B (1992) 0.90
Autoimmunity to collagen in adult periodontal disease: immunoglobulin classes in sera and tissue. J Periodontal Res (1992) 0.90
Production of hemopoietic growth factors and gamma-interferon by large granular lymphocytes from patients with T gamma lymphocytosis. Int J Cell Cloning (1987) 0.88
Antibodies to influenza A in a cluster of children with juvenile chronic arthritis. Br J Rheumatol (1988) 0.88
Effect of serine/threonine kinase inhibitors on motility of human lymphocytes and U937 cells. Immunology (1994) 0.88
Human monocyte killing of tumor cells: contribution of an extracellular cytotoxin. Adv Exp Med Biol (1982) 0.88
A simple, sensitive and reproducible assay for pyridoxal 5'-phosphate and 4-pyridoxic acid in human plasma. Clin Chim Acta (1999) 0.87
Cardiovascular and pulmonary function studies of a new sedative/analgetic (detomidine/Domosedan) for use alone in horses or as a preanesthetic. Acta Vet Scand Suppl (1986) 0.87
Characterisation of a new tryptic sub-fragment of human and rabbit IgG Fc fragment. Immunochemistry (1971) 0.86
Chemical synthesis, expression and product assessment of a gene coding for biologically active human tumour necrosis factor alpha. Protein Eng (1989) 0.85
Inhibition of protein kinase C results in a switch from a non-motile to a motile phenotype in diverse human lymphocyte populations. Immunology (1995) 0.85
Differential augmentation by recombinant human tumor necrosis factor-alpha of neutrophil responses to particulate zymosan and glucan. J Immunol (1990) 0.85
Active systemic lupus erythematosus is associated with the recruitment of naive/resting T cells. Br J Rheumatol (1996) 0.84
Tumour necrosis factor induction of ELAM-1 and ICAM-1 on human umbilical vein endothelial cells--analysis of tumour necrosis factor-receptor interactions. Cytokine (1992) 0.84
Chlamydia and Crohn's disease. Lancet (1979) 0.83
alpha 2HS-glycoprotein is expressed at high concentration in human fetal plasma and cerebrospinal fluid. Fetal Diagn Ther (1993) 0.82
Serum antibodies to anaerobic coccoid rods in patients with Crohn's disease or ulcerative colitis, and in medical and nursing staff. Br Med J (Clin Res Ed) (1981) 0.81
Guillain-Barré syndrome associated with Campylobacter enteritis in a child. J Pediatr (1986) 0.81
Motion rivalry impairs motion repulsion. Vision Res (2001) 0.81
Measurement of antibodies to Candida albicans as a screening test for humoral immunodeficiency. J Immunol Methods (1987) 0.81
Antibody response to anaerobic coccoid rods in Crohn's disease. J Clin Pathol (1986) 0.80
Human monocyte cytotoxin is not identical with lymphoblastoid lymphotoxin. Eur J Immunol (1985) 0.80
Cardiopulmonary bypass and complement activation. Involvement of classical and alternative pathways. Anaesthesia (1982) 0.80
Nitric oxide is produced during TNF killing of U937A cells but does not contribute to the cytotoxic process. Biochim Biophys Acta (1993) 0.79
Protein kinase C isotype expression and regulation of lymphoid cell motility. Immunology (1996) 0.79
A simple multistage field test for the prediction of anaerobic capacity in female games players. Br J Sports Med (2004) 0.79
Human neutrophil responses to pathogenic Escherichia coli are receptor-specific and selectively augmented by recombinant human tumor necrosis factor-alpha. J Infect Dis (1991) 0.79
Characterization of the normal lymphocyte population cytolytic to Burkitt's lymphoma cells of the EB2 cell line. Aust J Exp Biol Med Sci (1976) 0.79
Synthesis of the foetal protein fetuin by early developing neurons in the immature neocortex. J Neurocytol (1993) 0.78
Inducibility of class II major histocompatibility complex antigens by interferon gamma is associated with reduced tumorigenicity in C3H mouse fibroblasts transformed by v-Ki-ras. J Exp Med (1991) 0.78
Agglutinins to anaerobic bacteria in Crohn's disease and in Indian patients with diarrhoea. J Med Microbiol (1984) 0.78
Anti-tumour cytotoxin from macrophages: no correlation between cytotoxin adsorption by tumour cell lines and their cytotoxin susceptibility. Immunology (1984) 0.78
Reduced levels of alpha-1-antitrypsin in children exposed to high levels of air pollution. Biol Neonate (1993) 0.77
The selective augmentation by recombinant human tumour necrosis factor-alpha of neutrophil responses to pathogenic Escherichia coli. Immunology (1990) 0.77
Recurrent cerebral metastasis from a cardiac myxoma: case report and review of literature. Br J Neurosurg (2006) 0.77
Photographic and spectroscopic correlations of human cataracts. Ophthalmic Res (1989) 0.77
Inhibition of K cell function by human breast cancer sera. Br J Cancer (1976) 0.75
Use of the defined antigen substrate spheres system as a model for analysing possible mechanisms of inhibition-blockade of anti-tumour lymphocytotoxicity. Immunology (1975) 0.75
Antimicrobial properties of preterm breast milk cells. Arch Dis Child (1983) 0.75
Insertion of neonatal intercostal catheters. Crit Care Resusc (2003) 0.75
Zn-binding globulin in human fetal brain and liver: a marker for passive blood/CSF transfer of protein. Neuropathol Appl Neurobiol (1993) 0.75
Colonial morphology of tumour cells and susceptibility to cytolysis by tumour necrosis factor. The role of cellular fibronectin deposition in the extracellular matrix. Br J Cancer (1990) 0.75
Meningococcal infection and proteolytic control. J Clin Pathol (1978) 0.75
Bacterial identification using nitrocellulose blotting technique that incorporates ELISA to bacterial surface antigen. J Clin Pathol (1987) 0.75
Characterization of serum factors modulating splenic cytotoxicity in a syngeneic rat tumour system. Br J Cancer (1976) 0.75
Meningococcal endocarditis with profound acquired hypocomplementaemia. J Infect (1985) 0.75
Mixed lymphocyte reaction supernatants exert varied effects upon gingival fibroblasts in vitro. J Clin Lab Immunol (1985) 0.75
Continuous veno-venous hemodiafiltration using bicarbonate dialysate. Pediatr Nephrol (1997) 0.75
Antimicrobial effects of a macrophage-derived cytotoxin from the serum of BCG-primed rabbits (tumour necrosis serum). J Med Microbiol (1984) 0.75
Convulsions after miconazole overdose. Med J Aust (1987) 0.75
Serum and salivary immunoglobulin A and free secretory component in ulcerative colitis. Clin Allergy (1981) 0.75
Glued to the bedside: staff veterans. Interview by Barbara Barzoloski-O'Connor. Nurs Spectr (Wash D C) (1995) 0.75
Assessing a pregnant woman after trauma. Nursing (1990) 0.75
Immunofluorescence in cancer investigation and research. Ann N Y Acad Sci (1975) 0.75
Development of tumour cell resistance to tumour necrosis factor does not confer resistance to cytotoxic drugs. Eur J Cancer Clin Oncol (1989) 0.75
Extremely low phase noise UHF oscillators utilizing high-overtone, bulk-acoustic resonators. IEEE Trans Ultrason Ferroelectr Freq Control (1992) 0.75
Buccal biopsy in diagnosis of Crohn's disease. Lancet (1979) 0.75
Development of tumor cell resistance to tumor necrosis factor cytolysis results in reduced fibronectin binding and altered ganglioside expression. Cytokine (1991) 0.75
Letter: Spontaneous cytotoxic-activity as a test of human lymphocyte function. Lancet (1975) 0.75
[Not Available]. Immunol Today (1984) 0.75
Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects. Int J Clin Pharmacol Ther (2006) 0.75